Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Discovery
Sponsor : Mankind Pharma
Deal Size : $1,640.0 million
Deal Type : Acquisition
India's Mankind Pharma to Buy Bharat Serums in a $1.6 Billion Deal
Details : Through the acquisition of BSV, Mankind will enhance its pipelines including Endoprost (Carboprost Tromethamine), which is indicated for the treatment of post partum haemorrhage.
Brand Name : Endoprost
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 25, 2024
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Discovery
Sponsor : Mankind Pharma
Deal Size : $1,640.0 million
Deal Type : Acquisition
Lead Product(s) : Isoxsuprine Hydrochloride
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Recipient : Jagdale Industries
Deal Size : Undisclosed
Deal Type : Acquisition
Bharat Serums and Vaccines Acquires Key Women Health Brand Tidilan from Jagdale Industries
Details : Tidilan is currently available in tablet and injectable dosage forms. BSV has some of the leading women’s health brands such as Rhoclone, Hucog, Hucog 5000 HP, AntiD among others.
Brand Name : Tidilan
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 05, 2022
Lead Product(s) : Isoxsuprine Hydrochloride
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Recipient : Jagdale Industries
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Urinastatin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bharat Serums to assess sepsis drug Ulinastatin for Covid-19
Details : The trial will involve approximately 120 patients who have mild to moderate symptoms of acute ARDS. The drug is expected to improve recovery time and also mitigate mortality rates.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 09, 2020
Lead Product(s) : Urinastatin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
